The NHS has approved the use of vutrisiran, a treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), following NICE guidance. The drug, made by Alnylam, reduces harmful protein deposits in the heart and will be available for eligible patients in England and Wales. This marks a significant step in managing a progressive, often undiagnosed condition.